Kanghong Pharmaceutical Unit Buys Wealth Management Product for 1.70 Billion Yuan

MT Newswires Live
06/10

Chengdu Kanghong Pharmaceutical's (SHE:002773) unit, Chengdu Kanghong Biotech, purchased a wealth management product for 1.70 billion yuan, according to a Shenzhen bourse filing on Wednesday.

The wealth management product is a renminbi-denominated structured deposit from Bank of China (SHA:601988, HKG:3988), with a term of 204 days.

The product's annualized return is 0.60% if its linked indicator reaches or exceeds the observation level, but the annualized return would be at 1.75% if the linked indicated remains below the observation level throughout the observation period.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10